An open‐label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low‐grade non‐Hodgkin lymphoma

BACKGROUND In a previous study, the authors demonstrated that the combination of pentostatin (P) and rituximab (R) was well tolerated and was active in patients with low‐grade non‐Hodgkin lymphoma (NHL). In the current study, mitoxantrone (M) was added to P + R to evaluate the toxicity and efficacy...

Ausführliche Beschreibung